Ovid Therapeutics Inc. (OVID) Current Ratio
- Current ratio · latest quarter: Value 12.39×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 12.39× | Current assets / current liabilities. $123.62M ÷ $9.98M ≈ 12.39× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 123.62M USD | Assets, Current |
| Current obligations | 9.98M USD | Liabilities, Current |
| Cash and equivalents | 11.33M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 105.89M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 4.07M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $123.62M | $9.98M | $11.33M | $105.89M | (m) | (m) | $4.07M | (m) | 12.39× |
| 2026-03-31 | $160.15M | $15.75M | $94.06M | $61.46M | (m) | (m) | $8.88M | (m) | 10.17× |
| 2025-12-31 | $74.37M | $8.29M | $13.15M | $56.48M | (m) | (m) | $1.96M | (m) | 8.97× |
| 2025-09-30 | $28.82M | $6.80M | $20.61M | $4.99M | (m) | (m) | $1.71M | (m) | 4.24× |
| 2025-06-30 | $42.09M | $8.92M | $28.41M | $9.93M | (m) | (m) | $3.95M | (m) | 4.72× |
| 2025-03-31 | $45.92M | $9.31M | $21.14M | $21.86M | (m) | (m) | $1.95M | (m) | 4.93× |
| 2024-12-31 | $55.94M | $10.52M | $26.30M | $26.77M | (m) | (m) | $3.19M | (m) | 5.32× |
| 2024-09-30 | $65.83M | $11.63M | $15.02M | $47.70M | (m) | (m) | $2.71M | (m) | 5.66× |
| 2024-06-30 | $80.89M | $14.12M | $29.69M | $47.28M | (m) | (m) | $4.72M | (m) | 5.73× |
| 2024-03-31 | $93.17M | $8.90M | $30.77M | $59.49M | (m) | (m) | $3.60M | (m) | 10.47× |
| 2023-12-31 | $109.60M | $11.47M | $27.04M | $78.79M | (m) | (m) | $3.70M | (m) | 9.55× |
| 2023-09-30 | $91.71M | $8.66M | $57.44M | $29.64M | (m) | (m) | $1.22M | (m) | 10.59× |
| 2023-06-30 | $102.17M | $10.14M | $71.62M | $24.89M | (m) | (m) | $3.76M | (m) | 10.07× |
| 2023-03-31 | $119.52M | $6.72M | $63.05M | $54.67M | (m) | (m) | $1.83M | (m) | 17.78× |
| 2022-12-31 | $131.38M | $6.99M | $44.87M | $84.13M | (m) | (m) | $1.95M | (m) | 18.79× |
| 2021-12-31 | $190.48M | $14.80M | $187.80M | $0.00 | (m) | (m) | $7.13M | (m) | 12.87× |
| 2021-09-30 | $205.06M | $10.06M | $201.78M | (m) | (m) | (m) | $3.14M | (m) | 20.37× |
| 2021-06-30 | $215.87M | $11.29M | $212.17M | (m) | (m) | (m) | $909.52K | (m) | 19.12× |
| 2021-03-31 | $236.66M | $16.35M | $233.05M | (m) | (m) | (m) | $3.15M | (m) | 14.48× |
| 2020-12-31 | $74.84M | $22.06M | $72.03M | (m) | (m) | (m) | $5.45M | (m) | 3.39× |
| 2020-09-30 | $90.35M | $17.96M | $86.87M | (m) | (m) | (m) | $3.16M | (m) | 5.03× |
| 2020-06-30 | $44.11M | $14.59M | $41.25M | (m) | (m) | (m) | $4.63M | (m) | 3.02× |
| 2020-03-31 | $60.74M | $9.99M | $27.34M | $31.00M | (m) | (m) | $3.99M | (m) | 6.08× |
| 2019-12-31 | $79.81M | $10.53M | $41.90M | $34.84M | (m) | (m) | $3.26M | (m) | 7.58× |
| 2019-09-30 | $39.15M | $10.36M | $37.91M | (m) | (m) | (m) | $5.34M | (m) | 3.78× |
| 2019-06-30 | $53.61M | $9.18M | $47.36M | (m) | (m) | (m) | $2.05M | (m) | 5.84× |
| 2019-03-31 | $62.82M | $8.07M | $54.60M | $5.04M | (m) | (m) | $4.41M | (m) | 7.78× |
| 2018-12-31 | $44.27M | $8.84M | $36.49M | $5.01M | (m) | (m) | $3.76M | (m) | 5.01× |
| 2018-09-30 | $55.25M | $10.42M | $30.51M | $21.99M | (m) | (m) | $4.59M | (m) | 5.30× |
| 2018-06-30 | $65.19M | $7.50M | $22.54M | $40.06M | (m) | (m) | $3.43M | (m) | 8.70× |
| 2018-03-31 | $75.69M | $6.58M | $29.20M | $44.96M | (m) | (m) | $2.40M | (m) | 11.50× |
| 2017-12-31 | $88.59M | $6.02M | $87.13M | (m) | (m) | (m) | $2.03M | (m) | 14.71× |
| 2017-09-30 | $96.87M | $4.61M | $96.04M | (m) | (m) | (m) | $1.46M | (m) | 21.02× |
| 2017-06-30 | $107.31M | $7.07M | $106.12M | (m) | (m) | (m) | $3.57M | (m) | 15.19× |
| 2017-03-31 | $46.54M | $4.87M | $44.23M | (m) | (m) | (m) | $1.58M | (m) | 9.56× |
| 2016-12-31 | $52.41M | $3.73M | $51.94M | (m) | (m) | (m) | $857.17K | (m) | 14.04× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |